DDO-2093 - CAS# 2250024-74-7


Catalog No. Size PriceQuantity
M17118-C Contact sales@xcessbio.com for quotation $100

Description

DDO-2093 is a potent MLL1-WDR5 protein-protein interaction inhibitor (IC50=8.6 nM; Kd=11.6 nM) with antitumor activity. DDO-2093 selectively inhibits the catalytic activity of MLL complex.

Product information

CAS Number: 2250024-74-7

Molecular Weight: 614.11

Formula: C29H37ClFN9O3

Chemical Name: 1-[3-(5-amino-2-chloro-4-fluoro-3-methylbenzamido)-4-(4-methylpiperazin-1-yl)phenyl]-N-[3-(morpholin-4-yl)propyl]-1H-1, 2, 3-triazole-4-carboxamide

Smiles: CN1CCN(CC1)C1=CC=C(C=C1NC(=O)C1=CC(N)=C(F)C(C)=C1Cl)N1C=C(N=N1)C(=O)NCCCN1CCOCC1

InChiKey: MPTAUAHHFUFKAG-UHFFFAOYSA-N

InChi: InChI=1S/C29H37ClFN9O3/c1-19-26(30)21(17-22(32)27(19)31)28(41)34-23-16-20(4-5-25(23)39-10-8-37(2)9-11-39)40-18-24(35-36-40)29(42)33-6-3-7-38-12-14-43-15-13-38/h4-5,16-18H,3,6-15,32H2,1-2H3,(H,33,42)(H,34,41)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

DDO-2093 (5 μM; pretreated 7 days) inhibits MLL-fusion protein dependent genes expression (HOXA9 and Meis1).

In Vivo:

DDO-2093 (20 mg/kg-80 mg/kg; i.p.; every other day for 21 days) significantly suppresses the tumor size and weight in a dose-dependent manner.

Products are for research use only. Not for human use.

Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed